248 related articles for article (PubMed ID: 16079563)
1. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Tajima M
Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
3. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
4. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
5. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute promyelocytic leukemia with arsenic trioxide.
Tamm I; Paternostro G; Zapata JM
N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
8. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Carney DA
Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
[No Abstract] [Full Text] [Related]
10. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
11. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
13. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
14. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
15. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and neuroblastoma cytotoxicity.
Pettersson HM; Karlsson J; Pietras A; Øra I; Påhlman S
J Bioenerg Biomembr; 2007 Feb; 39(1):35-41. PubMed ID: 17549641
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
18. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au WY; Tam S; Fong BM; Kwong YL
Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
[No Abstract] [Full Text] [Related]
19. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
20. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
